Skip to main content
Immuno-Biological Laboratories Co., Ltd. logo

Immuno-Biological Laboratories Co., Ltd. — Investor Relations & Filings

Ticker · 4570 ISIN · JP3921300004 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2016-11-11 Interim / Quarterly Rep…
Country JP Japan
Listing T 4570

About Immuno-Biological Laboratories Co., Ltd.

https://www.ibl-japan.co.jp/en/

Immuno-Biological Laboratories (IBL) is a research and development-focused company that develops, manufactures, and supplies immunological research reagents and in-vitro diagnostic products for the global life sciences community. The company's core offerings include a comprehensive range of ELISA kits, antibodies, and cell culture-related products. IBL specializes in several key research areas, including aging, neurodegenerative disorders, kidney diseases, inflammatory diseases, and glucose/lipid metabolism. A notable proprietary technology is the LipoSEARCH® lipoprotein analyzing system, which uses patented GP-HPLC methods. The company also provides customized services to support specific research requirements.

Recent filings

Filing Released Lang Actions
四半期報告書－第35期第2四半期(2016/07/01－2016/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the regulatory reference (Financial Instruments and Exchange Act). It contains detailed financial statements, including the balance sheet, for the second quarter of the 35th fiscal period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2016
2016-11-11 Japanese
四半期報告書－第35期第1四半期(2016/04/01－2016/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet and income statement for the first quarter of the 35th fiscal period (April 1, 2016, to June 30, 2016). It includes management analysis of financial results and segment performance, meeting the criteria for an Interim/Quarterly Report (IR) rather than a mere announcement. Q1 2016
2016-08-12 Japanese
有価証券報告書－第34期(2015/04/01－2016/03/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard annual securities report required under the Financial Instruments and Exchange Act of Japan. It contains comprehensive financial statements, management discussion, and business overview for the fiscal year ending March 31, 2016. This corresponds to the definition of an Annual Report (10-K equivalent). FY 2016
2016-06-30 Japanese
四半期報告書－第34期第3四半期(2015/10/01－2015/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a Japanese 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, including the balance sheet, for the third quarter of the 34th fiscal year. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2015
2016-02-10 Japanese
四半期報告書－第34期第2四半期(2015/07/01－2015/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a Japanese 'Quarterly Report' (四半期報告書) filed under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis, and auditor review information for the second quarter of the 34th fiscal year. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2016
2015-11-13 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.